New antiepileptic drugs that are second generation to existing antiepileptic drugs

Expert Opinion on Investigational Drugs

Volumn 15, Issue 6, 2006, Pages 637-647

  Bialer, Meir ^a,b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Antiepileptic drugs; Carbamazepine; Felbamate; Gabapentin; Levetiracetam; Oxcarbazepine; Second generation to antiepileptic drugs; Valproic acid

Indexed keywords

1 [[(ALPHA ISOBUTANOYLOXYETHOXY)CARBONYL]AMINOMETHYL] 1 CYCLOHEXANE ACETIC ACID; AMIDINE; ANTICONVULSIVE AGENT; ARUNDIC ACID; BIA 2093; BRIVARACETAM; CARBAMAZEPINE; DEACETYLCOLCHICINE; DIZOCILPINE; ESLICARBAZEPINE ACETATE; ETIRACETAM; FELBAMATE; FLUOROFELBAMATE; GABAPENTIN; GANAXOLONE; HARKOSERIDE; ISOVALERAMIDE; LICARBAZEPINE; OXCARBAZEPINE; PLACEBO; PREGABALIN; RETIGABINE; RISPERIDONE; RUFINAMIDE; SELETRACETAM; SPD 421; STIRIPENTOL; TALAMPANEL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID DERIVATIVE; VALROCEMIDE; XP 13512;

ANTICONVULSANT ACTIVITY; APLASTIC ANEMIA; AREA UNDER THE CURVE; BINDING AFFINITY; BIPOLAR DISORDER; CLINICAL TRIAL; COGNITIVE DEFECT; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; EPILEPSY; HEADACHE; HUMAN; LIVER TOXICITY; NAUSEA; NONHUMAN; REVIEW; SINGLE DRUG DOSE; SOMNOLENCE; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TERATOGENICITY; TREATMENT OUTCOME;

AMINES; ANIMALS; ANTICONVULSANTS; BIPOLAR DISORDER; CARBAMAZEPINE; CYCLOHEXANECARBOXYLIC ACIDS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; EPILEPSY; GAMMA-AMINOBUTYRIC ACID; HUMANS; MOLECULAR STRUCTURE; RANDOMIZED CONTROLLED TRIALS; STRUCTURE-ACTIVITY RELATIONSHIP; VALPROIC ACID;

EID: 33745251005     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.15.6.637     Document Type: Review

References (68)

1. BLALER M, JOHANNESSEN SI, KUPFERBERG H et al.: Progress report on new antiepileptic drugs: a summary of the seventh Eilat conference on new antiepileptic drugs (EILAT VII). Epilepsy Res. (2004) 61:1-48.
2. BIALER M, WALKER MC, SANDER JWS: Pros and cons for the development of new antiepileptic drugs. CNS Drugs (2002) 16:285-289.
3. PERUCCA E: The new antiepileptic drugs: pharmacological and clinical aspects. Curr. Pharm. Design (2000) 6:839-860.
4. BIALER M: New antiepileptic drugs currently in clinical trials: is there a strategy in their development? Ther. Drug Monit. (2002) 24:85-90.
5. WALKER MC, SANDER JWS: The impact of new antiepileptic drugs on the prognosis of epilepsy: seizure freedom should be the ultimate goal. Neurology (1996) 46:912-914.
6. ISOHERRANEN N, YAGEN B, BIALER M: New CNS-active drugs which are second generation valproic acid: can they lead to development of the magic bullet? Curr. Opin. Neurol. (2003) 16:203-211.
7. LYNCH B, LAMBENG N, NOCKAS K et al.: The synaptic vesicle protein SV2A is the binding site for the antiepileptic levetiracetam. Proc. Natl. Acad. Sci. (2004) 101:9861-9866.
8. THOMPSON CD, KINTER MT, MacDONALD TL: Synthesis and in vitro reactivity of 3-carbamoyl-2-phenylpropionaldehyde and 2-phenylpropenal; putuative reactive metabolites of felbamate. Chem. Res. Toxicol. (1996) 9:1225-1229.
9. BIALER M, JOHANNESSEN SI, KUPFERBERG HJ et al.: Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference on new antiepileptic drugs (EILAT IV). Epilepsy Res. (1999) 34:1-41.
10. VOLOSOV A, XIANDONG S, PERUCCA E et al.: Enantioselective pharmacokinetics of 10-hydroxy carbazepine following oral administration of oxcarbazepine to healthy Chinese subjects. Clin. Pharmacol Ther. (1999) 66:547-553.
11. BIALER M: Oxcarbazepine: chemistry, biotransformation and pharmacokinetics. In: Antiepileptic Drugs, Levy RH, Mattson RH, Meldrum BS, Perucca E (Eds), Lippincott, Philadelphia, USA (2002) 5:459-465.
12. FLESCH G, CZENDLIK G, EHRHART E et al.: Pharmacokinetics of two enantiomers of the monohydroxy derivatives of oxcarbazepine in man. Eur. J. Pharm. Sci. (1999) 8:xii (Abstract).
13. JAIN KK: An assessment of rufinamide as an anti-epileptic in comparison with other drugs in clinical development. Expert Opin. Investig. Drugs (2000) 9:829-840.
14. BENES J, PARADA A, FIGUEIREDO AA et al.: Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz(b,f]a2epine-5-carboxamide derivative,. J. Med. Chem. (1999) 42:2582-2587.
15. ALMEIDA L, FALCAO L, MAIA J et al.: Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects. J. Clin. Phramacol. (2005) 45:1062-1006.
16. ALMEIDA L, SOARES DA SILVA P: Safety, tolerability and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic agent, during first administration to humans. Drugs R&D (2003) 4:269-284.
17. ALMEIDA L, SOARES DA SILVA P: Safety, tolerability and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young humans. J. Clin. Pharmacol. (2004) 44:906-918.
18. HAINZL D, PARADA A, SOARES DA SILVA P: Metabolism of two new antiepileptic drugs and their principal metabolites S(+)- and R(-)- 10, 11-dihydro-10-hydroxy carbamazepine. Epilepsy Res. (2001) 44:197-206.
19. ALMEIDA L, MAIA J, SOARES DA SILVA P: A double blind, add-on, placebo-controlled exploratory trial of eslicarbazepine acetate in patients with partial-onset seizures. Epilepsia (2005) 46(Suppl. 46):167-168.
20. PERUCCA E: Pharmacological and therapeutic properties of valproate. A summary after 35 years of clinical experience. CNS Drugs (2002) 16:695-714.
21. LOSCHER W: Valproate. Birkhauser Verlag, Basel, Switzerland (1999).
22. LOSCHER. W: Basic pharmacology of valproate. A review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs (2002) 16:669-694.
23. ISOHERRANEN N, YAGEN B, BLOTNIK S et al.: Characterization of the anticonvulsant activity and pharmacokinetics of propylisopropyl acetamide and its enantiomers. Br. J. Pharmacol. (2003) 138:602-613.
24. SOBOL E, BIALER M, YAGEN B: Tetramethylcyclopropyl analogue of a leading antiepileptic drug, valproic acid. Synthesis and evaluation of anticonvulsant activity of its amide derivatives. J. Med. Chem. (2004) 47:4316-4326.
25. WINKLER I, SOBOL E, YAGEN B et al.: Efficacy of antiepileptic tetramethylcyclopropyl analogues of valproic acid amides in a rat model for neuropathic pain, Neuropharmacology (2005) 49:1110-1120.
26. NAU H, SIEMENS H: Differentiation between valproate-induced anticonvulsant effect, teratogenicity and hepatotoxicity. Pharm. Weekbl. Sci. (1992) 14:101-105.
27. NAU H, HENDRICKX AG: Valproic acid teratogenesis. ISI Atlas Sci. Pharmacol, (1987) 1:52-56.
28. NAU H, HAUCK R-S, EHLERS K: Valproic acid induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms. Pharmacol. Toxicol. (1991) 69:310-321.
29. TANG W, PALATY J, ABBOTT FS: Time course of α-fluorinated valproic acid in mouse brain and serum and its effect on synaptosomal γ-aminobutyric acid levels in comparison to valproic acid. J. Pharmacol. Exp. Ther. (1997) 282:1163-1172.
30. TANG W, BOREL AG, FUJIMIYA T et al.: Fluorinated analogues as mechanistic probes in valproic acid hepatotoxicity: hepatic microvesicular steatosis and glutathione status. Chem. Res. Toxicol. (1995) 8:671-682.
31. NEUMAN MG, SHEAR NH, JACOBSON-BROWN PM et al.: CYP2E1 mediated modulation of valproic acid-induced hepatocytotoxicity. Clin. Biochem (2001) 34:211-218.
32. GRILLO MP, CHIELLINI G, TONELLI M et al.: Effect of α-fluorination of valproic acid on valproyl-S-acyl-CoA formation in vivo in rats. Drug Metab. Dispos. (2001) 29:1210-1215.
33. BIALER M: Clinical pharmacology of valpromide. Clin. Pharmacokinet. (1991) 20:114-122.
34. ISOHERRANEN N, KLEIN B, . ROEDER M et al.: Pharmacokinetic-pharmacodynamic relationships of (2S,3S)-valnoctamide and its stereoisomer (2R,3S)-valnoctamide in rodent models of epilepsy. Pharm. Res. (2003) 20:1293-1301.
35. SPIEGELSTEIN O, YAGEN B, LEVY RH et al.: Stereoselective pharmacokinetics and pharmacodynamics of propylisopropyl acetamide, a CNS-active chiral amide analog of valproic acid. Pharm. Res. (1999) 16:1582-1588.
36. WINKLER I, BLOTNIK S, SHIMSHONI J et al.: Efficacy of antiepileptic isomers of valproic acid and valpromide in a rat model for neuropathic pain. Br. J. Pharmacol. (2005) 146:198-208.
37. ISOHERRANEN N, WHITE HS, FINNELL RH et al.: Anticonvulsant profile and teratogenicity of N-methyl-tetamethylcyclopropyl carboxamide: a new anitiepileptic drug. Epilepsia (2002) 43:115-126.
38. SOBOL E, YAGEN B, WINKLER I et al.: Pharmacokinetics and metabolism of a new potent anticonvulsant agent 2,2,3,3-tetramethylcyclopropylcarbonylurea in rats. Drug Metab. Dispos. (2005) 33:1538-1546.
39. OKADA A, ONISHI Y, AOKI K et al.: Teratology studies of derivatives of tetramethylcyclopropyl amide analogues of valproic acid in mice. Birth Defect. Res. (Part B) (2006) 77:1-7.
40. SOBOL E, YAGEN B, WHITE HS et al.: Preclinical evaluation of 2,2,3,3-tetramethylcyclopropanecarbonylurea, a novel second generation to valproic acid, antiepileptic drug. Neuropharmacology (Submitted).
41. SHALTIEL G, SHAMIR A, SHAPIRO J et al.: Valproate decreases inositol biosynthesis. Biol. Psychiatr. (2004) 56:868-874.
42. ISOHERRANEN N, WOODHEAD JH, WHITE HS, BIALER M: Anticonvulsant profile of valrocemide (TV1901): a new antiepileptic drug. Epilepsia (2001) 42:831-836.
43. APPLEBAUM J, GAYDUK J, AGAM G et al.: Valnoctamide as valproate substitute with low teratogenic potential: double blind controlled clinical trial. Bipolar Disorder (2005) 7(Suppl. 2):30.
44. BIALER M, JOHANNESSEN SI, KUPFERBERG HJ et al: Progress report on new antiepileptic drugs: a summary of the sixth Eilat conference on new antiepileptic drugs (EILAT VI). Epilepsy Res. (2002) 51:31-71.
45. LABINER DM: DP-VPA. Curr. Opin. Invest. Drug. (2002) 3:921-923.
46. DE PAULIS T: ONO-2506. Curr. Opin. Investig. Drug. (2003) 4:863-867.
47. BLAHETA RA, CINTAL J: Anti-tumor mechanism of valproate: a novel role of an old drug. Med. Res. Rev. (2002) 22:491-511.
48. BLAHETA RA, NAU H, MICHAELIS M, CINTAL J: Valproate and valrpoate-analogues: potent tools to fight against cancer. Curr. Med. Chem. (2002) 9:1417-1433.
49. EYAL S, YAGEN B, SHIMSHONI J, BIALER M: Histone deacetylases inhibition and tumor cells cytotoxicity by CNS-active VPA constitutional isomers and derivatives. Biochem. Pharmacol. (2005) 69:1501-1508.
50. DWORKIN RH, KIRKPATRICK P: Pregabalin. Nat. Rev. (2005) 4:455-456.
51. BELLIOTTI TR, CAPIRIS T, EKHATO V et al.: Structure-activity relationships of pregabalin analogues that target the α2-δ protein. J.. Med. Chem. (2005) 48:2294-2307.
52. CUNDY KC, BRANCH R, CHERNOV-ROGAN T et al.: XP13512 [+/ 1]-1-([(α-isobutanoyloxyethoxy)-carbonyl]aminoethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug. I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporter. J. Pharmacol, Exp. Ther. (2004) 311:315-323.
53. CUNDY KC, ANNAMALAI T, BU L et al.: XP13512 [+/ 1]-I-([(α-isobutanoyloxyethoxy)- carbonyl]aminoerhyl)-I-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. J. Pharmacol. Exp. Ther. (2004) 311:324-333.
54. STEWART BH, KUGLER AH, TOMPSON PT, BOCKBRADER: A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of dose proportionality between increasing dose and drug levels in plasma. Pharm. Res. (1993) 10:276-281.
55. UCHINO H, KANAI Y, KIM DO K et al.: Transport of amino acid transporter 1 (LAT I): insights into the mechanism of saturable recognition. Mol. Pharmacol. (2002) 61:729-737.
56. CUNDY KC: Novel uses of drug transporters for drug delivery: a case study with gabapentin. Drug Transporters in ADME, Parisippany, New Jersey, USA (7-9 March 2005) (AAPS workshop).
57. MATAGNE A, KENDA B, MICHEL P, KLITGAARD H: Ucb34714, a new pyrrolidone derivative: comparison with levetiracetam in animal models for chronic epilepsy in vivo. Epilepsia (2003) 44(Suppl. 9):260.
58. KENDA B, MATANGE A, TALAG P et al.: Discovery of 4-substitiuted pyrrolidone butanamides as agents with significant antiepileptic activities. J. Med. Chem. (2004) 47:530-549.
59. WASTERLAIN C, SUCHOMELOVA L, MATANGE A et al.: Brivaracetam is a potent anticonvulsant in experimental status epilepticus. Epilepsia (2005) 46(Suppl. 8):219-220.
60. RIGO JM, NGUYEN L, HANS G et al.: Seletracetam (ucb44212): effect on inhibitory and excitatory neurotransmission. Epilepsia (2005) 46(Suppl. 8):110-111.
61. + currents in rat brain neurons in vitro. Epilepsia (2005) 46(Suppl. 8): 116.
62. 2+] increase in rat cortical neurons in vitro. Epilepsia (2005) 46(Suppl. 8):119-120.
63. MATANGE A, MICHEL P. KENDA B, KLTIGAARD H: Ucb44212, a new pyrrolidone derivative, suppresses seizures in animal models for chronic epilepsy in vivo. Epilepsia (2003) 46(Suppl. 6):121.
64. MAZARATI AM, SOFIAM RD, WASTERLIN CG: Anticonvulsant and antiepileptogenic effect of fluorofelbamate in experimental status epilepticus. Seizure (2002)1:423-430.
65. WALLIS RA, PANIZZON KL, NIQUET J et al.: Neuroprotective effect of the anticonvulsant, fluorofelbamate. Epilepsia (2000) 14(Suppl. 7):16.
66. WALKER MC, SANDER JW: New anti-epileptic drugs. Expert Opin. Investig. Drug. (1999) 8:1497-1510.
67. KLITGAARD H: Antiepileptic drug discovery: lessons from the past and future challenges. Acta Neurol. Scand. (2005) 112(Suppl. 181):68-72.
68. 50 values of antiepileptic drugs in mice and rats and their therapeutic doses and plasma levels. Epilepsy Behav. (2004) 5:866-872.